{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:25:57Z","timestamp":1792211157053,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T00:00:00Z","timestamp":1543017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10147-018-1371-7","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T23:23:17Z","timestamp":1543015397000},"page":"420-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites"],"prefix":"10.1007","volume":"24","author":[{"given":"Yoshiko","family":"Kawata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5175","authenticated-orcid":false,"given":"Kazunori","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuyo","family":"Mori-Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Arimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,24]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273\u2013282","journal-title":"Nat Rev Cancer"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11864-008-0068-y","volume":"9","author":"M Chung","year":"2008","unstructured":"Chung M, Kozuch P (2008) Treatment of malignant ascites. Curr Treat Options Oncol 9:215\u2013233","journal-title":"Curr Treat Options Oncol"},{"key":"1371_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589\u2013597","journal-title":"Eur J Cancer"},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L et al (2013) Malignant ascites: Pathophysiology and treatment. Int J Clin Oncol 18:1\u20139","journal-title":"Int J Clin Oncol"},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research. Front Oncol 3:1\u201312","journal-title":"Front Oncol"},{"key":"1371_CR6","doi-asserted-by":"crossref","first-page":"205846011557993","DOI":"10.1177\/2058460115579934","volume":"4","author":"M Meier","year":"2015","unstructured":"Meier M, Mortensen FV, Madsen HHT (2015) Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter. Acta Radiol Open 4:2058460115579934","journal-title":"Acta Radiol Open"},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1006\/gyno.1998.5215","volume":"71","author":"WH Gotlieb","year":"1998","unstructured":"Gotlieb WH, Feldman B, Feldman-Moran O et al (1998) Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 71:381\u2013385","journal-title":"Gynecol Oncol"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0885-3924(98)00037-2","volume":"16","author":"CW Lee","year":"1998","unstructured":"Lee CW, Bociek G, Faught W (1998) A survey of practice in management of malignant ascites. J Pain Symptom Manage 16:96\u2013101","journal-title":"J Pain Symptom Manage"},{"key":"1371_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/bja\/aep393","volume":"104","author":"J Boldt","year":"2010","unstructured":"Boldt J (2010) Use of albumin: an update. Br J Anaesth 104:276\u2013284","journal-title":"Br J Anaesth"},{"key":"1371_CR10","first-page":"2353","volume":"32","author":"T Ueda","year":"2012","unstructured":"Ueda T, Maehara M, Takahashi Y et al (2012) Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res 32:2353\u20132358","journal-title":"Anticancer Res"},{"key":"1371_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00002480-197700230-00189","volume":"23","author":"N Inoue","year":"1977","unstructured":"Inoue N, Yamazaki Z, Oda T et al (1977) Treatment of intractable ascites by continuous reinfusion of the sterilized cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23:699\u2013702","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"1371_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/1744-9987.12469","volume":"20","author":"K Kozaki","year":"2016","unstructured":"Kozaki K, IInuma M, Takagi T et al (2016) Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial 20:376\u2013382","journal-title":"Ther Apher Dial"},{"key":"1371_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/j.1525-1594.1997.tb00483.x","volume":"21","author":"S Katoh","year":"1997","unstructured":"Katoh S, Kojima T, Itoh K et al (1997) Usefulness of a nonmachinery based system for the reinfusion of cell-free and concentrated autogenous ascitic fluid. Artif Organs 21:1232\u20131238","journal-title":"Artif Organs"},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10147-011-0199-1","volume":"16","author":"K Matsusaki","year":"2011","unstructured":"Japanese CART Study Group, Matsusaki K, Ohta K, Yoshizawa A et al (2011) Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol 16:395\u2013400","journal-title":"Int J Clin Oncol"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ejso.2015.04.013","volume":"41","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Emoto S et al (2015) Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol 41:875\u2013880","journal-title":"Eur J Surg Oncol"},{"key":"1371_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1744-9987.2011.00973.x","volume":"15","author":"S Orimi","year":"2011","unstructured":"Orimi S, Mizuno K, Narahara M et al (2011) A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites. Ther Apher Dial 15:411\u2013414","journal-title":"Ther Apher Dial"},{"key":"1371_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jog.12763","volume":"41","author":"L Wang","year":"2015","unstructured":"Wang L, Okubo T, Shinsaka M et al (2015) Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites. J Obstet Gynaecol Res 41:1614\u20131620","journal-title":"J Obstet Gynaecol Res"},{"key":"1371_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/1744-9987.12049","volume":"18","author":"T Ito","year":"2014","unstructured":"Ito T, Hanafusa N, Fukui M et al (2014) Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites. Ther Apher Dial 18:87\u201392","journal-title":"Ther Apher Dial"},{"key":"1371_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0177303","volume":"12","author":"N Hanafusa","year":"2017","unstructured":"Hanafusa N, Isoai A, Ishihara T et al (2017) Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS One 12:1\u201321","journal-title":"PLoS One"},{"key":"1371_CR20","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.4161\/cc.29951","volume":"13","author":"M Cohen","year":"2014","unstructured":"Cohen M, Petignat P (2014) The bright side of ascites in ovarian cancer. Cell Cycle 13:2319","journal-title":"Cell Cycle"},{"key":"1371_CR21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3892\/mco.2014.335","volume":"2","author":"O Maeda","year":"2014","unstructured":"Maeda O, Ando T, Ishiguro K et al (2014) Safety of repeated cell\u2013free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol 2:1103\u20131106","journal-title":"Mol Clin Oncol"},{"key":"1371_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/1744-9987.12343","volume":"19","author":"S Maeda","year":"2015","unstructured":"Maeda S, Yabuuchi J, Nobuta H et al (2015) Characteristics of patients and their ascites who underwent repeated cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial 19:342\u2013348","journal-title":"Ther Apher Dial"},{"key":"1371_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/(SICI)1097-0142(19970225)81:1<16::AID-CNCR5>3.0.CO;2-E","volume":"81","author":"LJ Layfield","year":"1997","unstructured":"Layfield LJ, Mooney EE, Glasgow B et al (1997) What constitutes an adequate smear in fine-needle aspiration cytology of the breast? Cancer 81:16\u201321","journal-title":"Cancer"},{"key":"1371_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"1371_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jpainsymman.2003.05.003","volume":"26","author":"T Okuyama","year":"2003","unstructured":"Okuyama T, Wang XS, Akechi T et al (2003) Japanese version of the M.D. Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 26:1093\u20131104","journal-title":"J Pain Symptom Manage"},{"key":"1371_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1371_CR27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdw306","volume":"27","author":"M Malvezzi","year":"2016","unstructured":"Malvezzi M, Carioli G, Rodriguez T et al (2016) Global trends and predictions in ovarian cancer mortality. Ann Oncol 27:2017\u20132025","journal-title":"Ann Oncol"},{"key":"1371_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502","journal-title":"Nat Rev Cancer"},{"key":"1371_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2015.12.016","volume":"56","author":"JM Hansen","year":"2016","unstructured":"Hansen JM, Coleman RL, Sood AK (2016) Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131\u2013143","journal-title":"Eur J Cancer"},{"key":"1371_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty SL (2012) Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87","journal-title":"World J Gastrointest Surg"},{"key":"1371_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4009\/jsdt.34.335","volume":"34","author":"F Nakajima","year":"2001","unstructured":"Nakajima F, Shibahara N, Oka H et al (2001) Relationship between IL-6 levels and fever during ascites reinfusion therapy. Nihon Toseki Igakkai Zasshi 34:335\u2013338","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"1371_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/lt.24702","volume":"23","author":"A Kalra","year":"2017","unstructured":"Kalra A, Wedd JP, Bambha KM et al (2017) Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients withcirrhosis. Liver Transpl 23:155\u2013165","journal-title":"Liver Transpl"},{"key":"1371_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jog.12616","volume":"41","author":"K Nagasaka","year":"2015","unstructured":"Nagasaka K, Kawana K, Tomio K et al (2015) Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: a retrospective study. J Obstet Gynaecol Res 41:755\u2013762","journal-title":"J Obstet Gynaecol Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1371-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T19:24:19Z","timestamp":1574537059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1371-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,24]]},"assertion":[{"value":"22 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}